Heart Valve Replacement in India
Get Heart Valve Replacement at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Approximate cost range: $6,000 – $10,000
Heart Valve Replacement in UAE
Heart Valve Replacement at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Heart Valve Replacement Surgery is a life-restoring cardiac procedure performed to replace a diseased, stenotic, or regurgitant heart valve with a mechanical or biological prosthesis, restoring normal hemodynamic function and dramatically improving quality of life. Modern surgical and transcatheter techniques achieve procedural success rates exceeding 95% in experienced high-volume centers, with long-term survival outcomes comparable to international benchmarks. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited centers in the UAE, offering world-class cardiac surgery at a fraction of Western costs, with end-to-end concierge support from first consultation to post-operative discharge.
Hospital Stay: 7–12 days (ICU: 2–3 days; ward: 5–9 days) • Total Stay in Country (Fit-to-Fly): 4–6 weeks (short-haul); 6–8 weeks (long-haul intercontinental flight) • Success Rate: 95–98% procedural success; 10-year survival ~70–80% (age- and comorbidity-dependent)
What Is It?
The human heart contains four valves — mitral, aortic, tricuspid, and pulmonary — each acting as a one-way gate that directs blood flow through the cardiac chambers and into the systemic and pulmonary circulations. Valvular heart disease arises when one or more of these structures develops stenosis (narrowing that restricts forward flow) or regurgitation (incompetence that allows backward leakage), or both simultaneously in mixed disease. The two most clinically significant lesions requiring surgical intervention are severe aortic stenosis (most commonly degenerative calcific disease in patients over 65) and severe mitral regurgitation (rheumatic, myxomatous, or ischemic etiology). Left untreated, severe valvular disease imposes chronic pressure or volume overload on the myocardium, leading to ventricular hypertrophy, dilation, systolic dysfunction, pulmonary hypertension, atrial fibrillation, heart failure, and ultimately death. Symptomatic aortic stenosis, for example, carries a median survival of only 2–3 years without intervention.
The standard of care for valvular heart disease is established through rigorous guidelines published by the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC). Surgical Aortic Valve Replacement (SAVR) has been the gold standard for over six decades and remains the preferred approach for low- and intermediate-surgical-risk patients younger than 65–70 years. Transcatheter Aortic Valve Replacement (TAVR), introduced in 2002 and now refined through multiple generations of devices (SAPIEN 3 Ultra RESILIA, Evolut PRO+, Portico), has transformed care for high- and prohibitive-risk surgical patients and is now guideline-recommended for intermediate-risk patients as well. Mitral valve repair — when technically feasible — is preferred over replacement, as it preserves the subvalvular apparatus and native left ventricular geometry, yielding superior long-term LV function and survival.
The multidisciplinary Heart Team — comprising interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, and cardiac rehabilitation experts — evaluates every patient using validated risk stratification tools including the Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) score, the EuroSCORE II, and the Clinical Frailty Scale (CFS). This individualized risk-benefit analysis determines the optimal valve type, surgical approach (open sternotomy, minimally invasive, or transcatheter), and prosthesis selection (mechanical vs. bioprosthetic), ensuring each patient receives a precisely tailored treatment strategy.
Candidates
• ELIGIBLE PATIENTS (Surgical Indications per ACC/AHA / ESC Guidelines):
• Severe aortic stenosis with mean gradient >40 mmHg or valve area <1.0 cm² with symptoms (angina, syncope, dyspnea — the classic triad)
• Severe symptomatic mitral regurgitation with LVEF >30% and suitable anatomy for repair or replacement
• Severe asymptomatic aortic stenosis with declining LV ejection fraction (<50%), very severe stenosis (Vmax >5 m/s), or undergoing concurrent cardiac surgery
• Severe mitral stenosis (MVA <1.5 cm²) not amenable to balloon valvuloplasty due to calcified or bi-commissural fusion
• Structural valve deterioration (SVD) of a previously implanted bioprosthetic valve (valve-in-valve TAVR is an option)
• Infective endocarditis with valve destruction unresponsive to antibiotics, or with high embolic risk, large vegetations, or abscess formation
• Congenital bicuspid aortic valve disease with progressive stenosis or regurgitation meeting surgical thresholds
• REQUIRED PRE-OPERATIVE DIAGNOSTICS:
• Transthoracic Echocardiography (TTE): Primary imaging — quantifies valve gradients, valve area (continuity equation), regurgitant fraction, LV/RV dimensions and ejection fraction
• Transesophageal Echocardiography (TEE): Mandatory for precise mitral valve anatomy (Carpentier classification of leaflet prolapse/flail), annular sizing, and intraoperative guidance
• Cardiac CT Angiography (CCTA): Essential for TAVR planning — aortic annular sizing, iliofemoral access assessment, coronary height measurement, and aortic root geometry
• Coronary Angiography (Invasive): To rule out concomitant obstructive CAD requiring bypass grafting (CABG) at time of valve surgery
• 6-Minute Walk Test (6MWT) and Cardiopulmonary Exercise Testing (CPET): Functional capacity and exercise tolerance assessment
• Pulmonary Function Tests (PFTs): Especially in patients with suspected pulmonary comorbidities
• Carotid Doppler Ultrasound: Perioperative stroke risk assessment
• Blood Panel: CBC, coagulation profile (INR, aPTT), renal function (eGFR, creatinine), liver function, HbA1c, lipid panel, BNP/NT-proBNP
• Frailty Assessment: Clinical Frailty Scale (CFS), grip strength, 5-meter gait speed — essential for TAVR candidacy in elderly patients
• RELATIVE OR ABSOLUTE CONTRAINDICATIONS:
• Active systemic infection or bacteremia (surgery deferred until eradication, except in endocarditis emergencies)
• Severe, irreversible pulmonary hypertension with fixed PVR >8 Wood units (right heart failure precludes safe surgery)
• End-stage hepatic cirrhosis (Child-Pugh C) — prohibitive bleeding and hemodynamic risk
• Life expectancy <12 months due to non-cardiac malignancy or severe frailty (futility criterion)
• Lack of suitable vascular access for TAVR with no alternative surgical route
• Uncorrected coagulopathy or inability to tolerate anticoagulation (relative contraindication for mechanical valve selection)
Procedure
SURGICAL AORTIC VALVE REPLACEMENT (SAVR) — OPEN HEART (Gold Standard for Low/Intermediate Surgical Risk): Performed under cardiopulmonary bypass (CPB) with cardioplegic cardiac arrest. Median sternotomy or minimally invasive upper hemisternotomy (J-incision) provides access to the aortic root. The diseased native valve is excised, the annulus debrided and sized, and a prosthetic valve (mechanical or bioprosthetic) is seated with interrupted or continuous pledgeted sutures. Minimally invasive SAVR (mini-SAVR) via 5–8 cm right anterior minithoracotomy reduces blood loss, ICU duration, and accelerates sternal recovery. Sutureless valves (Perceval S, Intuity Elite) enable rapid deployment without time-consuming suturing, minimizing cross-clamp and CPB time — advantageous in complex re-operative or combined procedures.
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) — Preferred for High/Intermediate Risk and Age >75: A crimped bioprosthetic valve (balloon-expandable: Edwards SAPIEN 3 Ultra RESILIA; self-expanding: Medtronic Evolut PRO+ or FX; mechanically expanded: Boston Scientific ACURATE neo2) is delivered percutaneously via transfemoral access (preferred, 6–8 Fr sheath) under fluoroscopic and TEE/intracardiac echo guidance. The valve is deployed across the stenotic native annulus using rapid ventricular pacing (180–220 bpm) to minimize cardiac output during deployment. Alternative access routes (transapical, transaortic, transaxillary, transcaval) are employed when iliofemoral vessels are inadequate (<5.5 mm diameter, heavy calcification). TAVR eliminates sternotomy and CPB, with median procedural time of 60–90 minutes and same-day ICU extubation.
MITRAL VALVE REPAIR (Preferred over Replacement when feasible): Carpentier's functional classification (Type I: normal leaflet motion/annular dilation; Type II: leaflet prolapse/flail; Type III: restricted motion) guides repair strategy. Techniques include: quadrangular or triangular resection of posterior leaflet prolapse, artificial chordal reconstruction using ePTFE (Gore-Tex) neochordae, Alfieri edge-to-edge stitch for complex bileaflet prolapse, commissurotomy for rheumatic stenosis, and rigid/semi-rigid annuloplasty ring implantation (Carpentier-Edwards Physio II, Medtronic Profile 3D) to restore annular geometry and prevent future dilation. Repair durability rates exceed 90% freedom from reoperation at 10 years for degenerative disease in expert hands.
MITRAL VALVE REPLACEMENT (MVR) — When Repair is Not Feasible: Bioprosthetic mitral valves (pericardial: Carpentier-Edwards Perimount Magna Ease; porcine: Medtronic Mosaic) are preferred in patients >65 years or those unable to tolerate lifelong anticoagulation. Mechanical valves (St. Jude Medical Regent, CarboMedics) offer superior durability (>20 years) and are preferred in younger patients (<60–65 years) who can safely maintain therapeutic INR (2.5–3.5 for mitral position). Chordal preservation — retaining native subvalvular apparatus — is performed whenever possible during MVR to maintain LV geometry, function, and reduce the risk of posterior LV wall rupture.
MINIMALLY INVASIVE AND ROBOTIC APPROACHES: Robotic-assisted mitral valve surgery (da Vinci Surgical System) is offered at select high-volume centers in both India and the UAE. Four small port incisions (8–12 mm) replace thoracotomy, enabling 3D magnified visualization, wristed instrument articulation, and tremor filtration. Outcomes in experienced centers are equivalent to open surgery with significantly reduced blood transfusion, ICU stay (1–2 days), and total hospitalization (4–6 days). Patient selection requires adequate access, no prior right thoracotomy, and preserved LV function.
TRICUSPID AND PULMONARY VALVE PROCEDURES: Tricuspid regurgitation (functional or organic) is frequently addressed concomitantly during left-sided valve surgery via annuloplasty (Kay bicuspidalization, DeVega, or ring-based repair). Isolated tricuspid or pulmonary valve replacement (more common in congenital heart disease) uses bioprosthetic valves given the low-pressure right-sided circulation, avoiding lifelong anticoagulation.
VALVE PROSTHESIS SELECTION — KEY DECISION FRAMEWORK: Mechanical valves (bi-leaflet pyrolytic carbon): Lifelong warfarin required (INR 2.0–3.0 aortic; 2.5–3.5 mitral); 20+ year durability; preferred age <60 (aortic), <65 (mitral). Bioprosthetic valves (bovine pericardial/porcine): No routine anticoagulation after 3 months; 15–20 year durability in aortic position (less in mitral); preferred age >65, or patients with bleeding risk/lifestyle constraints. RESILIA tissue technology (Edwards) employs anti-calcification chemistry to extend bioprosthetic longevity.
Cost of Heart Valve Replacement: India vs. UAE
Heart Valve Replacement Surgery represents one of the most compelling value propositions in cardiac medical tourism, with costs in India and the UAE both significantly below those in the United States ($80,000–$150,000+) or Western Europe ($60,000–$100,000+). India's high-volume cardiac centers — many performing over 1,000 valve procedures annually — offer internationally benchmarked outcomes at 70–80% lower cost than Western countries, driven by lower overhead, lower physician fees, and government-regulated hospital pricing. The UAE offers a premium tier of care in world-class urban hospitals with a slightly higher cost structure than India but substantially below Western pricing, while offering the advantages of proximity for Middle Eastern, African, and European patients, English-Arabic bilingual care, and luxury hospitality infrastructure. Both destinations maintain JCI international accreditation, ensuring equivalent procedural safety standards. The cost ranges below reflect the total episode of care including surgeon and anesthesiologist fees, operating theater costs, ICU stay, ward stay, standard medications, prosthetic valve hardware, intraoperative imaging, and standard post-operative follow-up — but exclude international airfare, accommodation outside the hospital, and extended outpatient medications.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $7,000 – $18,000 | ~62% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $20,000 – $45,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TRAVEL EVALUATION (2–4 weeks before departure):
• GAF Healthcare coordinates remote pre-operative consultation: patient shares medical records, echocardiogram reports, coronary angiogram images, and recent blood work with the assigned cardiac surgery team in India or the UAE.
• The Heart Team reviews records and issues a preliminary treatment plan, surgical recommendation (SAVR vs. TAVR vs. repair), and cost estimate within 48–72 hours.
• GAF facilitates e-Medical Visa application for India (typically issued within 3–5 business days) or UAE entry visa arrangement, along with flight booking and pre-arrival accommodation confirmation.
PHASE 2 — ARRIVAL AND PRE-OPERATIVE WORKUP (Days 1–3 in country):
• Day 1: Airport pickup by GAF concierge team; check-in at hospital-adjacent accommodation for attendant; patient admitted to hospital.
• Day 1–2: Comprehensive in-hospital workup — repeat TTE/TEE, cardiac CT angiography for TAVR planning (if applicable), coronary angiogram (if not recent), full blood panel, anesthesia assessment, pulmonary function tests, carotid Doppler.
• Day 2–3: Heart Team case conference; final valve and approach selection; patient and family informed consent session with surgeon and cardiologist; pre-operative medications initiated (aspirin, statins, beta-blockers as indicated); anticoagulation bridging protocol if on warfarin.
PHASE 3 — SURGICAL PROCEDURE (Day 3–4):
• SAVR/MVR/Repair: Performed under general anesthesia. Cardiopulmonary bypass instituted (typically 90–150 minutes pump time; 60–90 minutes aortic cross-clamp for isolated valve). Intraoperative TEE confirms valve function, absence of paravalvular leak, and ventricular function before separation from bypass. Operative time: 3–5 hours (isolated single valve); 5–7 hours (combined valve + CABG or double valve).
• TAVR: Performed under general anesthesia or conscious sedation (monitored anesthesia care). Percutaneous femoral access; valve deployment under fluoroscopy and echo guidance. Procedural time: 60–90 minutes. Sheaths removed and access sites closed percutaneously (Perclose ProGlide, MANTA device).
PHASE 4 — ICU AND EARLY RECOVERY (Days 1–3 post-op):
• Patients are transferred to the Cardiac ICU intubated and sedated, typically extubated within 4–8 hours of SAVR (same-day for TAVR).
• Continuous hemodynamic monitoring: arterial line, central venous pressure, pulmonary artery catheter if indicated.
• Chest drains removed within 24–48 hours when output <100 mL/8 hours.
• Early mobilization: sitting upright Day 1 post-op; standing and walking with physiotherapist support Day 2.
• Rhythm monitoring for new-onset atrial fibrillation (affects 20–30% post-SAVR) — treated with rate control (beta-blockers, digoxin) and anticoagulation.
• Post-TAVR patients assessed for conduction abnormalities (new LBBB, complete heart block requiring permanent pacemaker implantation — ~10–15% with self-expanding valves).
PHASE 5 — STEP-DOWN WARD RECOVERY (Days 4–10 post-op):
• Transition from IV to oral medications: anticoagulation (warfarin for mechanical valves, initiated Day 1–2 with heparin bridge; aspirin + clopidogrel for TAVR for 3–6 months).
• Daily wound inspection; sternal wound care; incentive spirometry every 2 hours to prevent atelectasis.
• Cardiac rehabilitation Phase I: supervised progressive ambulation, education on sternal precautions (no lifting >2 kg, no pushing/pulling for 6–8 weeks), breathing exercises.
• Repeat TTE before discharge: confirms valve function, LVEF trajectory, and absence of pericardial effusion.
• INR monitoring and warfarin dose titration in mechanical valve patients before discharge.
PHASE 6 — DISCHARGE AND IN-COUNTRY RECUPERATION (Weeks 2–6):
• Discharge criteria: hemodynamically stable, ambulatory independently, wound healing satisfactory, INR therapeutic (if applicable), no fever, acceptable echocardiographic findings.
• Patients stay near the hospital in GAF-arranged accommodation for 2–4 weeks post-discharge for outpatient follow-up visits (wound check, INR, echo at 4 weeks).
• At the 4-week outpatient visit, the cardiac surgeon and cardiologist issue a Fit-to-Fly certificate if: no active wound complications, INR stable and therapeutic, no hemodynamically significant pericardial effusion, patient ambulating independently, no uncontrolled arrhythmias.
• Short-haul flights (under 4–5 hours): generally approved at 4–5 weeks post-op with compression stockings and in-flight ambulation every 1–2 hours.
• Long-haul flights (over 8 hours): recommended no earlier than 6–8 weeks post-op.
PHASE 7 — LONG-TERM FOLLOW-UP AND CONTINUITY OF CARE:
• GAF Healthcare provides a complete digital medical dossier (operative report, echocardiogram videos, discharge summary, prosthesis model/size card, anticoagulation records) for the patient's home cardiologist.
• Mechanical valve patients: Lifelong warfarin with target INR monitoring every 4 weeks; annual echocardiogram.
• Bioprosthetic valve patients: Annual TTE surveillance for structural valve deterioration (SVD); aspirin 75–100 mg daily long-term.
• TAVR patients: Dual antiplatelet therapy (aspirin + clopidogrel) for 3–6 months, then aspirin monotherapy. Annual CT or echo for valve surveillance.
Risks & Considerations
Heart Valve Replacement Surgery, like all open cardiac surgical procedures, carries a defined spectrum of perioperative and long-term risks that patients must understand before providing informed consent. Perioperative mortality for isolated aortic or mitral valve replacement in low-to-intermediate surgical risk patients at high-volume centers is 1–3% (STS PROM-aligned), rising to 5–10% in high-risk patients or combined valve + CABG procedures. Stroke and neurological injury — the most feared complication — occurs in 1–3% of SAVR cases and approximately 2–4% of TAVR cases, attributed to atheroembolism during aortic manipulation or valve debris dislodgement; cerebral embolic protection devices (Sentinel, Embrella) are employed in select TAVR cases. New-onset atrial fibrillation affects 20–40% of patients post-SAVR and typically requires temporary antiarrhythmic therapy and anticoagulation. Permanent pacemaker implantation is required in 3–8% of SAVR patients (higher with sutureless valves) and 10–20% of TAVR patients using self-expanding prostheses due to conduction system injury from the membranous septum. Paravalvular leak (PVL) — the presence of regurgitant flow around (not through) the prosthesis — is a recognized TAVR-specific complication in 5–15% of cases (mild PVL, often clinically insignificant; moderate-severe PVL requiring reintervention in 1–3%). Prosthetic valve endocarditis — infection of the implanted prosthesis — is a devastating late complication occurring in approximately 0.3–1.2% per patient-year, necessitating prolonged IV antibiotics and often re-operative surgery. Anticoagulation-related complications are lifelong considerations for mechanical valve recipients: thromboembolic events (stroke, TIA, valve thrombosis) occur at 0.5–2% per patient-year even with therapeutic INR, while major bleeding events (intracranial hemorrhage, GI hemorrhage) occur at 1–3% per patient-year. Structural valve deterioration (SVD) in bioprosthetic valves — defined by hemodynamically significant leaflet calcification and degeneration — begins to emerge at 10–12 years in the aortic position and earlier in the mitral position, particularly in younger patients, with cumulative freedom from SVD of approximately 70–80% at 15 years. Wound complications (sternal dehiscence, deep sternal wound infection) occur in 1–3% of open SAVR patients and are more common in diabetic, obese, or immunocompromised patients. Patients should discuss their individualized risk profile — calculated using the STS PROM score and EuroSCORE II — with their assigned cardiac surgeon during the pre-operative consultation facilitated by GAF Healthcare.
Top Hospitals for Heart Valve Replacement
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Fortis Memorial Research Institute
Gurgaon, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Top Doctors for Heart Valve Replacement
Internationally trained specialists in Cardiology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Nagesh Ayalasomayajula
MBBS, MS, MCh
Cardiothoracic & Heart Transplant Surgeon
Apollo Hospitals Jubilee Hills, Hyderabad, India
21+ Yearsof experience
Dr. Nagesh Ayalasomayajula is a Senior Consultant Cardiothoracic and Heart Transplant Surgeon based in Hyderabad with over 21 years of clinical expertise in advanced cardiac surgery. He holds an MBBS, MS in General Surgery, and an MCh in Cardiothoracic and Vascular Surgery (CTVS), making him one of India's most comprehensively trained cardiac surgeons. His qualifications reflect a rigorous progression through some of India's most competitive surgical… Read more
Dr. Krishna S Iyer
MBBS, MS (Surgery), M.Ch (Cardiothoracic Surgery), Fellowship in Infant Cardiac Surgery
Pediatric Cardiac Surgeon
Fortis Escorts Heart Institute, New Delhi, India
35+ Yearsof experience
Dr. Krishna S Iyer is one of India's most experienced and internationally recognised pediatric cardiac surgeons. As Executive Director of Pediatric and Congenital Heart Surgery at Fortis Escorts Heart Institute in Okhla, New Delhi, he has devoted his career to giving children with congenital heart disease — some of the most complex and delicate patients in all of medicine — the best possible chance at a full life. After his medical training, Dr. Iyer… Read more
Dr. Devi Shetty
MBBS, MS (General Surgery), MCh (Cardiothoracic Surgery), Fellowship in Cardiac Surgery
Cardiac Surgeon
Narayana Health, Bengaluru, India
38+ Yearsof experience
Dr. Devi Prasad Shetty is one of the most respected and widely recognised cardiac surgeons in the world. He is the founder and chairman of Narayana Health, a hospital chain that has redefined what affordable, high-quality cardiac care looks like — not only in India, but globally. Early in his career, Dr. Shetty trained at Guy's Hospital in London, one of the oldest teaching hospitals in Britain. He later served as personal physician to Mother Teresa, an… Read more
Dr. Naresh Trehan
MBBS, MS (General Surgery), Fellowship in Cardiothoracic Surgery
Cardiothoracic Surgeon
Medanta – The Medicity, Gurgaon, India
40+ Yearsof experience
Dr. Naresh Trehan is widely regarded as one of the most accomplished cardiovascular and cardiothoracic surgeons of his generation. With more than four decades of clinical practice spanning India and the United States, he has performed over 48,000 cardiac surgeries and has consistently ranked among the best heart surgeons in Asia. Born and educated in India, Dr. Trehan completed his advanced surgical training at New York University Medical Center, where he… Read more
Dr. Z S Meharwal
MBBS, MS (Surgery), MCh (Cardiothoracic Surgery), MNAMS
Cardiothoracic Surgeon
Fortis Escorts Heart Institute, New Delhi, India
30+ Yearsof experience
Dr. Z S Meharwal is part of the founding team of doctors at Fortis Escorts Heart Institute in Okhla, New Delhi, one of India's most respected cardiac centres. With more than 30 years of experience in cardiac surgery and over 30,000 surgeries to his credit — including many of the most complex heart operations performed in the country — he stands as one of the most accomplished cardiothoracic surgeons of his generation. Dr. Meharwal is a pioneer in many new… Read more
Frequently Asked Questions — Heart Valve Replacement
Heart Valve Replacement Surgery in India typically costs between $7,000 and $18,000 USD (all-inclusive of surgery, ICU, ward stay, prosthetic valve hardware, standard medications, and anesthesiologist fees), depending on the type of procedure (SAVR, TAVR, mitral repair, or double valve replacement), the prosthesis selected (mechanical vs. bioprosthetic, standard vs. RESILIA tissue), and whether concomitant procedures such as coronary artery bypass grafting (CABG) are required. In the UAE (Dubai or Abu Dhabi), the same procedure ranges from $20,000 to $45,000 USD — reflecting higher facility and physician fee structures, premium hospitality infrastructure, and DHA/JCI regulatory compliance costs. Both destinations are dramatically more affordable than the United States ($80,000–$150,000+) or the United Kingdom ($50,000–$90,000+) for equivalent-quality care in JCI-accredited hospitals. GAF Healthcare provides a detailed, itemized cost estimate for each individual patient within 48–72 hours of reviewing medical records, with no hidden fees.
The minimum recommended in-country stay following Heart Valve Replacement Surgery is 4–6 weeks for most patients, and this is a medically critical requirement — not a preference. After hospital discharge (typically Day 7–12 post-surgery), patients must remain near the treating hospital for a mandatory 2–4 week outpatient recovery phase before the cardiac surgeon and cardiologist can issue a Fit-to-Fly certificate. The Fit-to-Fly assessment evaluates: surgical wound healing and absence of sternal complications; echocardiographic confirmation of stable prosthetic valve function and absence of significant pericardial effusion; achievement of therapeutic anticoagulation (INR within target range for mechanical valve patients); independent ambulation without hemodynamic compromise; and absence of uncontrolled arrhythmias. Short-haul flights (under 4–5 hours) are generally cleared at 4–5 weeks post-operatively with mandatory compression stockings and in-flight leg exercises every 60–90 minutes to prevent deep vein thrombosis. Long-haul intercontinental flights (over 8 hours) are not recommended before 6–8 weeks post-surgery due to the risk of thromboembolic events, hemodynamic stress from prolonged immobility and cabin pressure, and the logistical danger of a medical emergency occurring mid-flight. TAVR patients typically have a shorter recovery trajectory and may be cleared for short-haul travel at 2–3 weeks if clinical criteria are met. GAF Healthcare arranges all post-discharge accommodation, follow-up appointments, and Fit-to-Fly documentation as part of its coordination package.
Heart Valve Replacement Surgery at GAF Healthcare's partner JCI-accredited hospitals in India and the UAE achieves a procedural success rate of 95–98%, defined as successful valve implantation or repair with restoration of normal or near-normal hemodynamics, absence of major paravalvular leak, and survival to hospital discharge without major adverse cardiovascular or cerebrovascular events (MACCE). These outcomes align with or exceed international benchmarks published by the Society of Thoracic Surgeons (STS) and the European Association for Cardio-Thoracic Surgery (EACTS). For TAVR specifically, device success rates (per VARC-3 criteria) consistently exceed 95% in experienced centers performing over 200 TAVR procedures annually. Long-term survival is strongly influenced by the patient's baseline clinical condition: 10-year survival for isolated aortic valve replacement in low-risk patients averages 70–75%; for mitral valve repair in degenerative disease, 10-year freedom from reoperation exceeds 90% in expert surgical centers. Mitral valve repair — when technically feasible — is associated with superior long-term survival compared to replacement, and GAF's partner institutions report repair rates above 90% for degenerative (Barlow's/fibroelastic deficiency) mitral disease. Each patient receives an individualized risk assessment using the STS PROM score and EuroSCORE II before surgery, providing a personalized estimate of procedural mortality and major complication probability.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated, physician-supervised medical tourism coordination service designed to eliminate logistical barriers for international patients seeking Heart Valve Replacement Surgery.
VISA AND ENTRY FACILITATION: For India: GAF Healthcare's dedicated visa team guides patients through the e-Medical Visa (e-MV) application — a streamlined Indian government portal specifically designed for medical travelers. The e-MV is typically issued within 3–5 business days of application with a hospital admission letter and treatment confirmation, and allows a 60-day stay with up to 3 entries. A companion/attendant visa (e-MVC) for one accompanying family member is applied simultaneously at no additional service charge. For the UAE (Dubai/Abu Dhabi): Citizens of over 50 countries — including the UK, USA, EU member states, Australia, and most GCC nations — receive visa-on-arrival or are visa-exempt for UAE entry. For patients from countries requiring advance visas, GAF Healthcare coordinates with the hospital's international patient services department to issue a formal invitation letter supporting the UAE medical visa application.
AIRPORT AND IN-COUNTRY TRANSFERS: GAF arranges door-to-door airport pickup using wheelchair-accessible vehicles for all cardiac patients, with a trained bilingual GAF escort at the arrival gate. All subsequent transfers — hotel to hospital for pre-operative workup, to the operating theater facility, and return transfers post-discharge — are pre-scheduled and included in the coordination package.
DEDICATED LANGUAGE SUPPORT: GAF Healthcare maintains a roster of certified medical interpreters fluent in Arabic, Russian, French, Swahili, Bangla, Dari, and other major patient languages. The assigned interpreter accompanies patients to all clinical consultations, surgical consent meetings, and discharge briefings, ensuring zero communication gaps between the medical team and patient/family. Written discharge summaries and medication instructions are translated into the patient's native language.
ACCOMMODATION FOR PATIENT AND ATTENDANT: GAF pre-negotiates discounted rates at hospital-adjacent serviced apartments and hotels within a 500-meter to 2-km radius of partner hospitals — critical for the 2–4 week post-discharge recovery stay before the Fit-to-Fly clearance. Accommodation options span budget-friendly guesthouses to five-star hotels, accommodating the spectrum of patient preferences. For high-acuity patients requiring closer medical observation, on-campus hospital guest suites (where available) are arranged.
CONTINUITY OF CARE COORDINATION: Upon the patient's return home, GAF Healthcare's medical coordination team provides a structured digital handover package — including operative reports, prosthetic valve specification cards, echocardiogram recordings, anticoagulation records, and a follow-up protocol — to the patient's home cardiologist, ensuring seamless continuity of post-operative cardiac care across borders. GAF's in-house nurse coordinators remain accessible via WhatsApp and email for 90 days post-discharge for non-emergency medical queries and home physician communication.
Patients Also Explore
Other treatments commonly sought by patients considering Heart Valve Replacement.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Brain Tumor Surgery
Neurology
Deep Brain Stimulation
Neurology